Key Insights

Highlights

Success Rate

88% trial completion (above average)

Published Results

21 trials with published results (11%)

Research Maturity

87 completed trials (47% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

6.5%

12 terminated out of 186 trials

Success Rate

87.9%

+1.4% vs benchmark

Late-Stage Pipeline

6%

12 trials in Phase 3/4

Results Transparency

24%

21 of 87 completed with results

Key Signals

21 with results88% success12 terminated

Data Visualizations

Phase Distribution

124Total
Not Applicable (46)
Early P 1 (4)
P 1 (33)
P 2 (29)
P 3 (11)
P 4 (1)

Trial Status

Completed87
Recruiting38
Unknown28
Terminated12
Active Not Recruiting12
Not Yet Recruiting7

Trial Success Rate

87.9%

Benchmark: 86.5%

Based on 87 completed trials

Clinical Trials (186)

Showing 20 of 20 trials
NCT06626412Not ApplicableActive Not RecruitingPrimary

Longitudinal SV2A PET and MRI in Premanifest HD

NCT06826612Phase 1RecruitingPrimary

A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

NCT06873334Phase 2Active Not RecruitingPrimary

Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease

NCT07326709Phase 3RecruitingPrimary

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

NCT07513844Not ApplicableRecruitingPrimary

Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease

NCT06667414RecruitingPrimary

Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

NCT06147414Recruiting

Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

NCT07378644Phase 2RecruitingPrimary

Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

NCT04713982Phase 2Active Not RecruitingPrimary

Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

NCT07451613Phase 1RecruitingPrimary

Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease

NCT07516899Phase 1Not Yet RecruitingPrimary

Mass Balance Study of [14C] LPM3770164 in Healthy Participants

NCT01882062Phase 2CompletedPrimary

Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease

NCT06634628Early Phase 1RecruitingPrimary

iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009

NCT07253038RecruitingPrimary

Evaluation of Three Tests to Assess Social Cognition in Huntington Disease

NCT05686551Phase 2Active Not RecruitingPrimary

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

NCT06546488RecruitingPrimary

Cognitive Assessment Tools for Huntington's Disease.

NCT07409597Not ApplicableNot Yet RecruitingPrimary

Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease

NCT04012411Not ApplicableRecruitingPrimary

Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease

NCT05326451Not ApplicableRecruitingPrimary

Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease

NCT06843252Not ApplicableRecruitingPrimary

Home-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease

Scroll to load more

Research Network

Activity Timeline